BACKGROUND AND PURPOSE: Retinoids, including all-trans retinoic acid (tRA), have dose-dependent pro-fibrotic effects in experimental kidney diseases. To understand and eventually prevent such adverse effects, it is important to establish relevant in vitro models and unravel their mechanisms. EXPERIMENTAL APPROACH: Fibrogenic effects of retinoids were assessed in NRK-49F renal fibroblasts using picro-Sirius red staining for collagens and quantified by spectrophotometric analysis of the eluted stain. Other methods included RT-qPCR, immunoassays and matrix metalloproteinase (MMP) activity assays. KEY RESULTS: With or without TGF-β1, tRA was dose-dependently pro-fibrotic, notably increasing collagen accumulation. tRA and TGF-β1 additively suppressed expression of mRNA for MMP2, 3 and 13 and suppressed MMP activity. tRA, in the presence of TGF-β1, induced plasminogen activator inhibitor-1 (PAI-1) mRNA and they additively induced PAI-1 protein expression. A PAI-1 inhibitor, a pan-retinoic acid receptor (RAR) antagonist and a pan-retinoid X receptor (RXR) antagonist each partially prevented the pro-fibrotic effect of tRA. The dose-dependent pro-fibrotic effects of a pan-RXR agonist were similar to those of tRA. A pan-RAR agonist showed weaker, less dose-dependent pro-fibrotic effects and the pro-fibrotic effects of RARα and RARβ-selective agonists were even smaller. An RARγ-selective agonist did not affect fibrogenesis. CONCLUSIONS AND IMPLICATIONS: An in vitro model for the pro-fibrotic effects of retinoids was established in NRK-49F cells. It was associated with reduced MMP activity and increased PAI-1 expression, and was probably mediated by RXR and RAR. To avoid or antagonize the pro-fibrotic activity of tRA, further studies on RAR isotype-selective agonists and PAI-1 inhibitors might be of value.
BACKGROUND AND PURPOSE:Retinoids, including all-trans retinoic acid (tRA), have dose-dependent pro-fibrotic effects in experimental kidney diseases. To understand and eventually prevent such adverse effects, it is important to establish relevant in vitro models and unravel their mechanisms. EXPERIMENTAL APPROACH: Fibrogenic effects of retinoids were assessed in NRK-49F renal fibroblasts using picro-Sirius red staining for collagens and quantified by spectrophotometric analysis of the eluted stain. Other methods included RT-qPCR, immunoassays and matrix metalloproteinase (MMP) activity assays. KEY RESULTS: With or without TGF-β1, tRA was dose-dependently pro-fibrotic, notably increasing collagen accumulation. tRA and TGF-β1 additively suppressed expression of mRNA for MMP2, 3 and 13 and suppressed MMP activity. tRA, in the presence of TGF-β1, induced plasminogen activator inhibitor-1 (PAI-1) mRNA and they additively induced PAI-1 protein expression. A PAI-1 inhibitor, a pan-retinoic acid receptor (RAR) antagonist and a pan-retinoid X receptor (RXR) antagonist each partially prevented the pro-fibrotic effect of tRA. The dose-dependent pro-fibrotic effects of a pan-RXR agonist were similar to those of tRA. A pan-RAR agonist showed weaker, less dose-dependent pro-fibrotic effects and the pro-fibrotic effects of RARα and RARβ-selective agonists were even smaller. An RARγ-selective agonist did not affect fibrogenesis. CONCLUSIONS AND IMPLICATIONS: An in vitro model for the pro-fibrotic effects of retinoids was established in NRK-49F cells. It was associated with reduced MMP activity and increased PAI-1 expression, and was probably mediated by RXR and RAR. To avoid or antagonize the pro-fibrotic activity of tRA, further studies on RAR isotype-selective agonists and PAI-1 inhibitors might be of value.
Authors: M Ebisawa; H Umemiya; K Ohta; H Fukasawa; E Kawachi; G Christoffel; H Gronemeyer; M Tsuji; Y Hashimoto; K Shudo; H Kagechika Journal: Chem Pharm Bull (Tokyo) Date: 1999-12 Impact factor: 1.645
Authors: Richard L Beard; Tien T Duong; Min Teng; Elliott S Klein; Andrew M Standevan; Roshantha A S Chandraratna Journal: Bioorg Med Chem Lett Date: 2002-11-04 Impact factor: 2.823
Authors: Yufeng Huang; Masashi Haraguchi; Daniel A Lawrence; Wayne A Border; Ling Yu; Nancy A Noble Journal: J Clin Invest Date: 2003-08 Impact factor: 14.808
Authors: Ana Gutiérrez-Fernández; Clara Soria-Valles; Fernando G Osorio; Jesús Gutiérrez-Abril; Cecilia Garabaya; Alina Aguirre; Antonio Fueyo; María Soledad Fernández-García; Xose S Puente; Carlos López-Otín Journal: EMBO J Date: 2015-05-19 Impact factor: 11.598
Authors: Sarah D Ahadome; Rose Mathew; Nancy J Reyes; Priyatham S Mettu; Scott W Cousins; Virginia L Calder; Daniel R Saban Journal: JCI Insight Date: 2016-08-04
Authors: Sarah D Ahadome; David J Abraham; Suryanarayana Rayapureddi; Valerie P Saw; Daniel R Saban; Virginia L Calder; Jill T Norman; Markella Ponticos; Julie T Daniels; John K Dart Journal: JCI Insight Date: 2016-08-04
Authors: Daniel Berner; Ursula Hoja; Matthias Zenkel; James Julian Ross; Steffen Uebe; Daniela Paoli; Paolo Frezzotti; Robyn M Rautenbach; Ari Ziskind; Susan E Williams; Trevor R Carmichael; Michele Ramsay; Fotis Topouzis; Anthi Chatzikyriakidou; Alexandros Lambropoulos; Periasamy Sundaresan; Humaira Ayub; Farah Akhtar; Raheel Qamar; Juan C Zenteno; Marisa Cruz-Aguilar; Yury S Astakhov; Michael Dubina; Janey Wiggs; Mineo Ozaki; Friedrich E Kruse; Tin Aung; André Reis; Chiea Chuen Khor; Francesca Pasutto; Ursula Schlötzer-Schrehardt Journal: Hum Mol Genet Date: 2019-08-01 Impact factor: 6.150